Showing results (1-10 of 296) with videos related to
Sort By:
Pageof 30
Journal of the National Comprehensive Cancer Network : JNCCN|May 20, 2026
Real-World Representation in Prostate Cancer Clinical Trials: Needs and OpportunitiesHannah D McManus, Daniel J George, Jeffrey W ShevachClinical Advances in Hematology & Oncology : H&O|April 22, 2025
Genetics of prostate cancerJeffrey W Shevach, Kathleen A CooneyJournal of the National Cancer Center|February 25, 2026
Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancerFurong Huang, Kexin Li, Jeffrey W Shevach, et al.Case Reports in Oncology|December 1, 2025
High-Risk Prostate Cancer in a Patient with Untreated Prolactinoma and Castrate-Level Testosterone Suppression: A Case ReportTara A Seibert, Afreen Shariff, Hannah D McManusClinical Genitourinary Cancer|June 4, 2023
Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus NivolumabHannah D McManus, Dylan Zhang, Fides R Schwartz, et al.European Urology Oncology|May 31, 2020
Risk Assessment and Considerations for Proper Management of Elderly Men with Advanced Prostate Cancer: A Systematic ReviewJeffrey W Shevach, Adam B Weiner, Rachel N Kasimer, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 12, 2025
Reducing unnecessary blood cultures in oncology through algorithmic stewardship in a tertiary medical centerMaría I Font Mera, Cameron Oswalt, Hannah D McManus, et al.American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 19, 2023
Triplet Strategies in Metastatic Clear Cell Renal Cell Carcinoma: A Worthy Option in the First-Line Setting?Catherine C Fahey, Jeffrey W Shevach, Ronan Flippot, et al.Urology|September 17, 2002
Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylateDaniel J GeorgeClinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinomaDaniel J GeorgePageof 30